The GetSkinHelp WalkING Clinic will be travelling through the streets of Downtown Toronto and help people get the medical attention they need and are waiting for
November 14, 2022 07:07 ET
|
Skinopathy
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Skinopathy, the company behind GetSkinHelp, are helping people avoid months of waiting thanks to The GetSkinHelp WalkING Clinic which will bring the doctor...
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
October 12, 2022 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
$11+ Billion Dermatology Devices Market Size to Grow at 11.2% CAGR, Globally, by 2028 - Growing Prevalence of Skin Cancers and Skin Disorders
September 30, 2022 08:00 ET
|
The Insight Partners
New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology Devices Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast...
Global Immune Checkpoint Inhibitors Market to Surpass US$ 3,902.9 Million by 2030, Says Coherent Market Insights (CMI)
August 29, 2022 08:40 ET
|
CMI
Seattle, Aug. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immune checkpoint inhibitors market is estimated to be valued at US$ 1,444.7 million in 2022 and is...
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
Prostate Cancer Nuclear Medicine Diagnostics Market to Hit $1,315.66 million by 2028 at 10.6% CAGR - Says, The Insight Partners
July 25, 2022 10:30 ET
|
The Insight Partners
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global...
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Monoclonal Antibodies for Oncology Global Market Report 2022
July 08, 2022 05:43 ET
|
Research and Markets
Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed...
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
June 03, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...